$AMLX News
Last published 4d ago
- 4d agoAMLXGuggenheim 3rd Annual Healthcare Innovation Conference - AMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsI'll just talk louder. Well, good morning, everybody, and thanks for joining us for today's another fireside discussion here at Guggenheim's Healthcare Innovations Conference. Really pleased to have the team from Amelix
- 1w agoAMLXAmylyx Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1mo agoAMLXAmylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingBusiness WireLate-breaking oral presentation to feature Phase 3 topline data highlighting avexitide’s efficacy and safety Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it
- 1mo agoAMLXSTIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - AMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsGreat. Excited to get into the next session here with the Amilex Pharmaceuticals team. I have co-CEOs Justin Klee and Josh Cohen. Obviously, a super exciting time for AmileX. I think everyone knows the story well, but ma
- 1mo agoAMLXSTIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - AMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsGreat. Excited to get into the next session here with the Amilex Pharmaceuticals team. I have co-CEOs Justin Klee and Josh Cohen. Obviously, a super exciting time for AmileX. I think everyone knows the story well, but ma
- 1mo agoAMLXAmylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic ForumBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on
- 1mo agoAMLXAmylyx Pharmaceuticals - 1773807 - AMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsPerfect. So welcome, everybody. I'm Kayla McGurk. I am a member of the investment banking team at Morgan Stanley. It is my pleasure, my absolute pleasure, to welcome Josh Cohen and Justin Klee, co-founders of Amilex, to
- 2mo agoAMLXALKSTortugas Neuroscience Announces Appointment of Jim Frates to Board of DirectorsBusiness WireTortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial
- 2mo agoAMLXAmylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare ConferenceBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will
- 2mo agoAMLXAmylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common StockBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public
- 2mo agoAMLXAmylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common StockBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition,
- 2mo agoAMLXAmylyx Phase 3 LUCIDITY Topline Results Conference Call - AMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsGood morning. My name is Kath, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amelix Pharmaceuticals Phase 3 Licidity Topline Data Conference Call. All participants wi
- 2mo agoAMLXAmylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric HypoglycemiaBusiness WireLUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003) LUCIDITY met all secondary
- 2mo agoAMLXAmylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026Business WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18,
- 3mo agoAMLXAmylyx Second Quarter 2026 Earnings Conference Call - AMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsGood morning. My name is Carrie, and I will be your conference operator today. At this time, I would like to welcome everyone to the MLX Pharmaceuticals 7th Quarter 2026 Earnings Conference Call. All participants will be
- 3mo agoAMLXAmylyx Pharmaceuticals Reports Second Quarter 2026 Financial ResultsBusiness WireLast participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated in late August
- 3mo agoAMLXAmylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026Business WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its second quarter 2026 financial results on Thursday, August 6, 2026. Amylyx’s senior management team will host a
- 4mo agoAMLXAmylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026Business WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European
- 5mo agoAMLXAmylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026Business WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced two poster presentations at the upcoming Endocrine Society's Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago,
- 6mo agoAMLXAmylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical InvestigationBusiness WirePeer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple outcomes related
- 6mo agoAMLX2026 GLOBAL HEALTHCARE CONFERENCEAMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsAll right, everybody, we're going to get going here with our next company presenter at the B of A Annual Healthcare Conference. My name is Jason Gerber. I cover pharma and biotech, and I'm pleased to be introducing Amlex
- 6mo agoAMLXAmylyx First Quarter 2026 Earnings Conference CallAMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsGood morning. My name is Kate and I will be your conference operator today. At this time, I would like to welcome everyone to the Amulist Pharmaceuticals First Quarter 2026 Earnings Conference Call. All participants will
- 6mo agoAMLXAmylyx Pharmaceuticals Reports First Quarter 2026 Financial ResultsBusiness WireTopline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide
- 6mo agoAMLXAmylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person: Bank of
- 6mo agoAMLXAmylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric HypoglycemiaBusiness WireThe Expanded Access Program allows eligible adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery access to avexitide, an investigational, first-in-class glucagon-like peptide-1 receptor
- 6mo agoAMLXAmylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026Business WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its first quarter 2026 financial results on Thursday, May 7, 2026. Amylyx's senior management team will host a conference call and audio
- 7mo agoAMLX25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE - AMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, everyone. Thanks, Q, for joining the session with Amelix. I'm Ami Fadia, biotech analyst here at Needham, and it's my pleasure to be hosting Jim Frey, CFO of the company. Jim, thank you so much for taking o
- 7mo agoAMLXAmylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation will take place on
- 7mo agoAMLXAmylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric HypoglycemiaBusiness WireLast participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participants Topline data readout on track; anticipated in Q3 2026 LUCIDITY is evaluating the
- 8mo agoAMLXAmylyx Fourth Quarter/Full Year 2025 Earnings Conference CallAMYLYX PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, everyone. My name is Jim, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amelix Pharmaceuticals fourth quarter and full year 2025 earnings conference cal
- 8mo agoAMLXAmylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireRecruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway
- 8mo agoAMLXAmylyx Pharmaceuticals to Participate in Upcoming March Investor ConferencesBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person: TD Cowen
- 8mo agoAMLXAmylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026Business WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. Amylyx's senior management team will host a
- 11mo agoAMLXAmylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA TrialBusiness Wire- AMX0114 was generally well-tolerated, with no treatment-related serious adverse events - Amylyx will proceed with opening enrollment of second cohort - Data are being presented at the 36th International Symposium on
- 1y agoAMLXAmylyx Pharmaceuticals Reports Third Quarter 2025 Financial ResultsBusiness WireCompletion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide expected in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected into 2028, through the potential approval and commercial
- 1y agoAMLXAmylyx Pharmaceuticals to Present at Upcoming Investor ConferencesBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the following upcoming conferences, which are being conducted in-person: Guggenheim 2nd Annual
- 1y agoAMLXAmylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025Business WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its third quarter 2025 financial results on Thursday, November 6, 2025. Amylyx' senior management team will host a conference call and
- 1y agoAMLXKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ:...
- 1y agoAMLXKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) breached their
- 1y agoAMLXHUMUNCYVSTSAttention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX): Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) as
- 1y agoAMLXKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ:...
- 1y agoAMLXAmylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common StockBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10.00 per
- 1y agoAMLXAmylyx Pharmaceuticals Announces Proposed Public Offering of Common StockBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being
- 1y agoAMLXAmylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoAMLXAmylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoAMLXAmylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)Business Wire- AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24 - AMX0035 continued to be generally well-tolerated Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the
- 1y agoAMLXAmylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in Boston and
- 1y agoAMLXAmylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAMLXAmylyx Pharmaceuticals Reports Second Quarter 2025 Financial ResultsBusiness WireCompletion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated in first half of 2026 Cash, cash equivalents, and marketable securities of $180.8
- 1y agoAMLXAmylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025Business WireAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its second quarter 2025 financial results on Thursday, August 7, 2025. Amylyx' senior management team will host a conference call and